Shares of biotech company Biogen were moving higher on Thursday after the company received an upgrade from an analyst. RBC Capital Markets analyst Brian Abrahams upgraded Biogen stock on hopes for its Alzheimer’s drugs. Abrahams sees an $8 billion peak opportunity if the CMS decision comes out in Aduhelm’s favor and if Biogen succeeds with … Continue reading “Biogen Gets Analyst Upgrade and Announces Layoffs”
Tag: Alzheimer’s Disease
Biotech & Pharma
Biogen Shares Explode on FDA Approval of Alzheimer’s Drug
Shares of biotech company Biogen were soaring on Monday after Wall Street learned that the…
June 7, 2021
Biotech & Pharma
Biogen Surprises Wall Street With This News
Biogen announced on Tuesday that its Alzheimer's treatment was ready to start the regulatory approval…
October 23, 2019
Hot Stocks
Biogen Shares Explode on Positive Results from Alzheimer’s Drug Trial
Shares of Biogen were climbing higher on Friday after the company and Eisai announced the…
July 6, 2018
Biotech & Pharma
Cantabio Pharmaceuticals Inc. (CTBO) Targets Alzheimer’s
More than 700,000 seniors are expected to die this year from Alzheimer's disease. It is…
June 8, 2016